UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM S-1 REGISTRATION STATEMENT

UNDER
THE SECURITIES ACT OF 1933

89bio, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or organization)

2834
(Primary Standard Industrial Classification Code Number)

36-4946844 (I.R.S. Employer Identification Number)

142 Sansome Street, Second Floor San Francisco, CA 94104 (415) 500-4614

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Rohan Palekar Chief Executive Officer 89bio, Inc. 142 Sansome Street, Second Floor San Francisco, CA 94104 (415) 500-4614

(Name, address, including zip code, and telephone number, including area code, of agent for service)

With copies to:

Ryan A. Murr Branden C. Berns Gibson, Dunn & Crutcher LLP 555 Mission Street San Francisco, CA 94105 (415) 393-8373 Divakar Gupta Jonie I. Kondracki Robert W. Phillips Charles S. Kim Cooley LLP 101 California Street San Francisco, CA 94111 (415) 693-2000

Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective.

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. \Box

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

333-239688

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. \Box

If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. \Box

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer		Accelerated file	er	
Non-accelerated filer		Smaller reportii	ng company	\boxtimes
		Emerging grow	th company	\boxtimes
	rth company, indicate by check mark if the registrant has elected not to use the extential accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Accounting the Securities Acco		r complying w	rith
	CALCULATION OF REGISTRATION FEE			
	Title of Each Class of Securities to be Registered	Proposed Maximum Offering Price(1)	Amount of Registration Fee(1)	
Common Stock, par value		\$13,965,600	\$1,813	
the option to purcha	ent shall become effective upon filing with the Securities and Exchange Commi			

EXPLANATORY NOTE AND INCORPORATION BY REFERENCE

Pursuant to Rule 462(b) under the Securities Act of 1933, as amended, 89bio, Inc., a Delaware corporation ("89bio"), is filing this registration statement with the Securities and Exchange Commission (the "SEC"). This registration statement relates to the public offering of securities contemplated by the Registration Statement on Form S-1 (File No. 333-239688) (the "Registration Statement") filed by 89bio with the SEC on July 6, 2020, which was declared effective on July 7, 2020.

89bio is filing this registration statement for the sole purpose of increasing the aggregate offering price of shares of common stock to be offered by 89bio in the public offering by \$13,965,600, which represents no more than 20% of the maximum aggregate offering price set forth in the Calculation of Registration Fee table contained in the Registration Statement. The information set forth in the Registration Statement and all exhibits to the Registration Statement are hereby incorporated by reference into this registration statement.

The required opinion and consents are listed on the Exhibit Index attached hereto and filed herewith.

EXHIBIT INDEX

Exhibit Number	Description of Exhibit	
5.1	Opinion of Gibson, Dunn & Crutcher LLP	
23.1	Consent of Independent Registered Public Accounting Firm.	
23.2	Consent of Independent Registered Public Accounting Firm.	
23.3	Consent of Gibson, Dunn & Crutcher, LLP (included in Exhibit 5.1).	
24.1	Power of Attorney (incorporated by reference to Exhibit 24.1 of the Form S-1 Registration Statement (Registration No. 333-239688)).	

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California, on July 7, 2020.

89bio, Inc.

By: /s/ Rohan Palekar

Rohan Palekar Chief Executive Officer Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities set forth opposite their names and on the date indicated above.

Signature	Title	Date
/s/ Rohan Palekar	Chief Executive Officer	July 7, 2020
Rohan Palekar	(principal executive officer)	
/s/ Ryan Martins	Chief Financial Officer	July 7, 2020
Ryan Martins	(principal financial and accounting officer)	
*	Chairman	July 7, 2020
Steven M. Altschuler, M.D.	<u>—</u>	y ,
*	Director	July 7, 2020
Derek DiRocco, Ph.D.	2.400.	outy 7, 2020
*	Director	July 7, 2020
Gregory Grunberg, M.D.	Breetoi	July 7, 2020
*	Director	July 7, 2020
Michael Hayden, M.B., Ch.B., Ph.D.	Director	July 7, 2020
*	Di .	I 1 7 2020
Anat Naschitz	Director	July 7, 2020
Lota Zoth	Director	July 7, 2020
Lota Zotti		
*D /c/ Rohan Dalakar		

*By: /s/ Rohan Palekar

Rohan Palekar Attorney-in-fact



Gibson, Dunn & Crutcher LLP

555 Mission Street San Francisco, CA 94105-1921 Tel 415.393.8200 www.gibsondunn.com

Client: 26925-00005

July 7, 2020

89bio, Inc. 142 Sansome Street, Second Floor San Francisco, CA 94104

Re: 89bio, Inc.

Registration Statement on Form S-1

Ladies and Gentlemen:

We have examined the Registration Statement on Form S-1 of 89bio, Inc., a Delaware corporation (the "<u>Company</u>"), filed with the Securities and Exchange Commission (the "<u>Commission</u>") on the date hereof pursuant to Rule 462(b) (the "<u>Additional Registration Statement</u>") promulgated under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), in connection with the offering by the Company of up to 517,040 shares (which includes shares that may be sold upon exercise of the underwriters' option to purchase additional shares) of the Company's common stock (the "<u>Common Stock</u>"), par value \$0.001 per share (the "<u>Shares</u>"). The Additional Registration Statement incorporates by reference the Registration Statement on Form S-1, File No. 333-239688 (the "<u>Registration Statement</u>"), of the Company, filed with the Commission pursuant to the Securities Act.

In arriving at the opinion expressed below, we have examined originals, or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of specimen Common Stock certificates and such other documents, corporate records, certificates of officers of the Company and of public officials and other instruments as we have deemed necessary or advisable to enable us to render the opinions set forth below. In our examination, we have assumed without independent investigation the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to us as copies.

Based upon the foregoing, and subject to the assumptions, exceptions, qualifications and limitations set forth herein, we are of the opinion that the Shares, when issued against payment therefor as set forth in the Registration Statement, will be validly issued, fully paid and non-assessable.

Beijing • Brussels • Century City • Dallas • Denver • Dubai • Frankfurt • Hong Kong • Houston • London • Los Angeles • Munich New York • Orange County • Palo Alto • Paris • San Francisco • São Paolo • Singapore • Washington D.C.

GIBSON DUNN

July 7, 2020 Page 2

We consent to the filing of this opinion as an exhibit to the Additional Registration Statement, and we further consent to the use of our name under the caption "Legal Matters" in the Registration Statement and the prospectus that forms a part thereof, which are incorporated by reference into the Additional Registration Statement. In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission.

Very truly yours,

Sincerely,

/s/ Gibson, Dunn & Crutcher LLP

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in this Registration Statement on Form S-1 filed pursuant to Rule 462(b) of the Securities Act of 1933, as amended, of our report dated March 18, 2020 relating to the financial statements of 89bio, Inc., appearing in the Annual Report on Form 10-K of 89bio, Inc. for the year ended December 31, 2019. We also consent to the reference to us under the heading "Experts" in the Registration Statement on Form S-1 (File No. 333-239688) incorporated by reference in this Registration Statement.

/s/ Deloitte & Touche LLP San Francisco, California July 7, 2020

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the use in this Registration Statement on Form S-1 filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, of our report dated August 15, 2019, except for the retroactive effect of both the 1-for-6.217 reverse stock split and the reorganization, as described in Note 1, as to which the date is October 28, 2019 relating to the financial statements of 89bio, Inc. (operating as 89Bio, Ltd. prior to the reorganization described in Note 1) appearing in the Annual Report on Form 10-K of 89bio, Inc. for the year ended December 31, 2019. We also consent to the reference to us under the heading "Experts" in Registration Statement on Form S-1 (File No. 333-239688).

/s/ Brightman Almagor Zohar & Co.

A Firm in the Deloitte Global Network

Tel Aviv, Israel

July 7, 2020